Corporate ActionJun 18, 2026, 09:17 AM
COSCIENS Biopharma Appoints Permanent CEO; Approves Share Capital Amendment
AI Summary
COSCIENS Biopharma Inc. announced the results of its Annual General and Special Meeting, where shareholders approved all proposed matters, including the re-election of directors, re-appointment of auditors, and a significant share capital amendment. The amendment involves a 1-for-150 common share consolidation followed by an immediate 50-for-1 split. Additionally, Peter H. Puccetti, previously Interim CEO, has been appointed as the permanent full-time President and CEO, effective immediately, with a focus on strengthening operational performance and shareholder value creation.
Key Highlights
- Peter H. Puccetti appointed permanent President and CEO, effective immediately.
- Shareholders approved the re-election of all six director nominees.
- Deloitte LLP re-appointed as the Company's auditors.
- Approved a 1-for-150 common share consolidation.
- Approved an immediate subsequent 50-for-1 common share split.
- All matters presented at the Annual General and Special Meeting were approved.
- Peter Puccetti aims to strengthen operational performance and align resources.
Price Impact
More from CSCIF